Literature DB >> 15706414

Stimulation of MCF-7 tumor progression in athymic nude mice by 17beta-estradiol induces WISP-2/CCN5 expression in xenografts: a novel signaling molecule in hormonal carcinogenesis.

Gibanananda Ray1, Snigdha Banerjee, Neela K Saxena, Donald R Campbell, Peter Van Veldhuizen, Sushanta K Banerjee.   

Abstract

There was 100% solid tumor formation following inoculation of MCF-7 cells. However, MCF-7 tumor progression was significantly greater in the mice exposed to 17beta-estradiol (17beta-E2) compared to unexposed mice. WISP-2/CCN5 mRNA expression was correspondingly increased in 17beta-E2 exposed MCF-7 tumors compared to unexposed xenografts. Moreover, estrogen exposure followed by anti-estrogen tamoxifen treatment drastically inhibited the tumor growth and WISP-2 expression in nude mice. Therefore, the study suggests that higher WISP-2/CCN5 expression by estrogen may be associated with the estrogen-induced growth of MCF-7 tumors in vivo. Finally, overexpression of WISP-2/CCN5 may be considered as a prognostic marker of estrogen-sensitive tumor growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706414

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.

Authors:  Yadwinder S Deol; Mohd W Nasser; Lianbo Yu; Xianghong Zou; Ramesh K Ganju
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

2.  The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis.

Authors:  Inamul Haque; Archana De; Monami Majumder; Smita Mehta; Douglas McGregor; Sushanta K Banerjee; Peter Van Veldhuizen; Snigdha Banerjee
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

3.  Novel combination of 2-methoxyestradiol and cyclophosphamide enhances the antineoplastic and pro-apoptotic effects on S-180 ascitic tumour cells.

Authors:  Srabantika Mallick; Atish Barua; Goutam Paul; Samarendra Nath Banerjee
Journal:  J Cell Commun Signal       Date:  2017-08-10       Impact factor: 5.782

4.  CCN5/WISP-2: A micromanager of breast cancer progression.

Authors:  Sushanta K Banerjee; Snigdha Banerjee
Journal:  J Cell Commun Signal       Date:  2012-04-10       Impact factor: 5.782

5.  A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.

Authors:  Suman Kambhampati; Roger A Rajewski; Mehmet Tanol; Inamul Haque; Amlan Das; Snigdha Banerjee; Saheli Jha; Douglas Burns; Emma Borrego-Diaz; Peter J Van Veldhuizen; Sushanta K Banerjee
Journal:  Mol Cancer Ther       Date:  2013-01-03       Impact factor: 6.261

6.  Slit-2 induces a tumor-suppressive effect by regulating beta-catenin in breast cancer cells.

Authors:  Anil Prasad; Vikram Paruchuri; Anju Preet; Farida Latif; Ramesh K Ganju
Journal:  J Biol Chem       Date:  2008-07-08       Impact factor: 5.157

7.  Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Authors:  Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

Review 8.  Eyeing the Cyr61/CTGF/NOV (CCN) group of genes in development and diseases: highlights of their structural likenesses and functional dissimilarities.

Authors:  Izabela Krupska; Elspeth A Bruford; Brahim Chaqour
Journal:  Hum Genomics       Date:  2015-09-23       Impact factor: 4.639

9.  WISP2 promotes cell proliferation via targeting ERK and YAP in ovarian cancer cells.

Authors:  Zi-Qing Shi; Zi-Yan Chen; Yao Han; Heng-Yan Zhu; Meng-Dan Lyu; Han Zhang; Yi Zhang; Liu-Qing Yang; Wei-Wei Pan
Journal:  J Ovarian Res       Date:  2020-07-25       Impact factor: 4.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.